{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-076234","form_type":"8-K","ticker":"KZR","cik":"0001645666","company_name":"Kezar Life Sciences, Inc.","filed_at":"2024-06-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.409763+00:00","generated_at":"2026-06-01T02:51:56.047904+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Kezar Life Sciences stockholders reject Say-on-Pay, approve reverse split authorization","bullets":["Say-on-Pay advisory vote failed: 27.2M against vs 19.8M for.","Reverse stock split authorized (ratio 1:2 to 1:20) at Board's discretion.","Directors Christopher Kirk and John Fowler elected with >33M votes each.","KPMG ratified as independent auditor for FY2024 with overwhelming support.","Company will hold annual Say-on-Pay votes until 2030 after advisory vote."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-076234","json":"https://secwatch.observer/filing/0000950170-24-076234.json","markdown":"https://secwatch.observer/filing/0000950170-24-076234.md","text":"https://secwatch.observer/filing/0000950170-24-076234.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645666/000095017024076234/0000950170-24-076234-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645666/000095017024076234/kzr-20240618.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T02:51:56.047904+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}